The association between XRCC1 Arg399Gln polymorphism and risk of leukemia in different populations: a meta-analysis of case-control studies.

Abstract:

BACKGROUND:Associations between Arg399Gln single-nucleotide polymorphism (SNP) in the XRCC1 gene and leukemia susceptibility have been studied extensively, however, the results are inconsistent. The aim of this study was to determine these associations using meta-analytical methods. METHODS:A meta-analysis was performed to examine the associations between XRCC1 Arg399-Gln SNP and leukemia risk. A literature search of PubMed and Web of Science databases was conducted to identify relevant studies published up to March 10, 2015. The references of the retrieved articles were also screened. All the statistical analyses were conducted using Review Manager software. RESULTS:The XRCC1 Arg399Gln SNP was found to be associated with increased childhood risk of acute lymphoblastic leukemia among Asians under the dominant (odds ratio [OR] 2.11, 95% confidence interval [CI] 1.50-2.97, P<0.0001), allele contrast (OR 1.72, 95% CI 1.33-2.23, P<0.0001), and homozygote contrast (OR 2.34, 95% CI 1.25-4.36, P=0.008) models. However, no association was found in Caucasians between the SNP and risk of either chronic myeloid leukemia or chronic lymphocytic leukemia under any contrast model. CONCLUSION:The findings of the current meta-analysis indicate that the XRCC1 Arg399Gln SNP is a risk factor for childhood lymphoblastic leukemia in Asians.

journal_name

Onco Targets Ther

journal_title

OncoTargets and therapy

authors

Wang F,Zhao Q,He HR,Zhai YJ,Lu J,Hu HB,Zhou JS,Yang YH,Li YJ

doi

10.2147/OTT.S92752

subject

Has Abstract

pub_date

2015-11-06 00:00:00

pages

3277-87

issn

1178-6930

pii

ott-8-3277

journal_volume

8

pub_type

杂志文章
  • Associations between the NUDT15 R139C polymorphism and susceptibility to thiopurine-induced leukopenia in Asians: a meta-analysis.

    abstract:Background and aim:Despite several studies being conducted to examine the associations between the NUDT15 R139C polymorphism and thiopurine-induced leukopenia in the Asian population, the results remain inconsistent. This meta-analysis determined the risk of thiopurine-induced leukopenia conferred by the NUDT15 R139C p...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S177007

    authors: Liu Y,Meng Y,Wang L,Liu Z,Li J,Dong W

    更新日期:2018-11-23 00:00:00

  • HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer - a study of the OVCAD Consortium.

    abstract:PURPOSE:Hypoxia is a common phenomenon encountered in solid cancers, leading to chemotherapy resistance and therefore to aggressiveness of the disease. The homeostatic response to hypoxia is mediated by hypoxiainducible factor-1 (HIF-1). The aim of this study was to investigate the impact of HIF1α in patients with prim...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S65373

    authors: Braicu EI,Luketina H,Richter R,Cacsire Castillo-Tong D,Lambrechts S,Mahner S,Concin N,Mentze M,Zeillinger R,Vergote I,Sehouli J

    更新日期:2014-09-11 00:00:00

  • Bone Marrow Stromal Antigen 2 is a Potential Unfavorable Prognostic Factor for High-Grade Glioma.

    abstract:Background:Bone marrow stromal antigen 2 (BST2) is considered as a transmembrane glycoprotein and plays essential roles in innate immunity. It has been recently reported that up-regulation of BST2 was associated with the development of breast carcinoma. However, the clinical significance of BST2 in glioma has not been ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S258631

    authors: Shi H,Luo K,Huang W

    更新日期:2020-08-26 00:00:00

  • Akt/mTOR-Mediated Autophagy Confers Resistance To BET Inhibitor JQ1 In Ovarian Cancer.

    abstract:Background:Bromodomain and extra-terminal domain inhibitors like JQ1 have proved to be promising epigenetic agents for the treatment of malignant ovarian carcinoma. However, the resistance of ovarian cancer cells to BET inhibitors has not been elucidated. In this study, we investigated the potential mechanisms underlyi...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S220267

    authors: Luan W,Pang Y,Li R,Wei X,Jiao X,Shi J,Yu J,Mao H,Liu P

    更新日期:2019-10-03 00:00:00

  • The expression sequence tag is an effective method for screening DNA segments that predict urinary bladder transitional cell carcinoma prognosis.

    abstract:PURPOSE:We validated the use of expression sequence tags (ESTs) as an effective method of screening for DNA segments that could predict urothelial cell carcinoma and for identifying ESTs with such predictive value. PATIENTS AND METHODS:From 2004 to 2009, eleven patients were enrolled in this study: six with high-grade...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S69239

    authors: Yang PS,Hsu YC,Lin YH,Hou CP,Chen CL,Chang PL,Juang HH,Tsui KH

    更新日期:2014-09-30 00:00:00

  • Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer.

    abstract:Background:Although there have been great advances in mechanisms and therapeutic methods of prostate cancer, the mortality rate of prostate cancer remains high. The castration-resistant prostate cancer (CRPC), which develops from hormone-sensitive prostate cancer, foreshadows a more dismal outcome. Concomitant with the...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S159777

    authors: Wang K,Ruan H,Xu T,Liu L,Liu D,Yang H,Zhang X,Chen K

    更新日期:2018-05-28 00:00:00

  • Cyclic adenosine monophosphate-responsive element-binding protein activation predicts an unfavorable prognosis in patients with hepatocellular carcinoma.

    abstract:AIM:To investigate the clinical significance of cyclic adenosine monophosphate-responsive element-binding (CREB) and phosphorylated CREB (pCREB) expression in human hepatocellular carcinoma (HCC). MATERIALS AND METHODS:Immunohistochemistry and Western blot analyses were performed to detect the expression and subcellul...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S63594

    authors: Yu L,Guo X,Zhang P,Qi R,Li Z,Zhang S

    更新日期:2014-05-29 00:00:00

  • TRIM3 Negatively Regulates Autophagy Through Promoting Degradation of Beclin1 in Ewing Sarcoma Cells.

    abstract:Background and aim:Ewing sarcoma (ES) is an aggressive neoplasm predominantly occurring in adolescents and has a poor prognosis when metastasized. In the current study, we were aiming to investigate the function of TRIM3 in autophagy in ES cells. Methods:The expression of TRIM3 in Ewing sarcoma tissues and normal tiss...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S219777

    authors: Lu Q,Zhang Y,Ma L,Li D,Li M,Liu P,Li J

    更新日期:2019-12-30 00:00:00

  • Pancreatic neuroendocrine neoplasms at magnetic resonance imaging: comparison between grade 3 and grade 1/2 tumors.

    abstract:BACKGROUND:The grading of pancreatic neuroendocrine neoplasms (PanNENs) is associated with the choice of treatment strategy. The aim of this study is to identify the magnetic resonance imaging (MRI) features in differentiating pancreatic neuroendocrine tumors (PanNETs) grade 1/2 (G1/G2) and pancreatic neuroendocrine ca...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S127803

    authors: Guo C,Chen X,Xiao W,Wang Q,Sun K,Wang Z

    更新日期:2017-03-07 00:00:00

  • STRN-ALK Fusion in Lung Adenocarcinoma with Excellent Response Upon Alectinib Treatment: A Case Report and Literature Review.

    abstract::Non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK) rearrangement benefit from treatment with ALK inhibitors. Therefore, the identification of druggable ALK fusions is necessary for NSCLC treatment. More than 90 fusion partners of ALK have been reported in NSCLC patients, but the striatin...

    journal_title:OncoTargets and therapy

    pub_type:

    doi:10.2147/OTT.S282933

    authors: Su C,Jiang Y,Jiang W,Wang H,Liu S,Shao Y,Zhao W,Ning R,Yu Q

    更新日期:2020-12-04 00:00:00

  • Resveratrol decreases B-cell lymphoma-2 expression and viability in GH3 pituitary adenoma cells of the rat.

    abstract:OBJECTIVE:Resveratrol is a phytoestrogen with various antiproliferative and proapoptotic effects. This in vitro study aimed to analyze the effect of resveratrol on the viability and expression of modulators of apoptosis in GH3 pituitary adenoma cells of the rat. METHODS:GH3 cells were incubated with resveratrol concen...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S45154

    authors: Voellger B,Kirches E,Wilisch-Neumann A,Weise A,Tapia-Perez JH,Rupa R,Mawrin C,Firsching R

    更新日期:2013-09-16 00:00:00

  • miR520a-3p suppresses cell proliferation and metastasis by inhibiting the p65-NFκB pathway in glioblastoma.

    abstract:Background:miR520a-3p has previously had its antitumorigenic role in various types of cancers revealed, and been predicted as a posttranscriptional regulator of the NFκB-subunit RELA gene. Thus, miR520a-3p could function in carcinogenesis through suppressing RELA. Methods:Expression of miR520a-3p and RELA mRNA was qua...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S208889

    authors: Zhang JQ,Hong B

    更新日期:2019-08-14 00:00:00

  • Pathological complete response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with unresectable BRAF V600E-mutant malignant melanoma of the gallbladder.

    abstract::Historically, patients with locally advanced or metastatic melanoma have an extremely poor prognosis. In recent years, major breakthroughs in cutaneous melanoma treatment have led to remarkable improvements in patient outcomes. However, there are limited published data on the efficacy of these novel therapies in the t...

    journal_title:OncoTargets and therapy

    pub_type:

    doi:10.2147/OTT.S177111

    authors: Yu Z,Quiroz E,Shen Y,Jaiyesimi IA

    更新日期:2018-12-04 00:00:00

  • Effects of Vitamin K3 Combined with UVB on the Proliferation and Apoptosis of Cutaneous Squamous Cell Carcinoma A431 Cells.

    abstract:Purpose:Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer and its incidence continues to rise yearly. Photodynamic therapy (PDT) is a non-invasive form of cancer therapy, which utilizes the combined action of a photosensitizer, light, and oxygen molecules to selectively cause cellul...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S228792

    authors: Shi S,Zheng G,Yang C,Chen X,Yan Q,Jiang F,Jiang X,Xin Y,Jiang G

    更新日期:2019-12-31 00:00:00

  • The Combination of Plasma Fibrinogen Concentration and Neutrophil Lymphocyte Ratio (F-NLR) as a Prognostic Factor of Epithelial Ovarian Cancer.

    abstract:Objective:Growing epidemiological evidence supports that coagulation cascades and cancer-associated inflammation are associated with recurrence and survival of epithelial ovarian cancer (EOC). This study aimed to assess the clinical significance of the combination of plasm fibrinogen and neutrophil lymphocyte ratio (F-...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S264118

    authors: Yang J,Ma J,Cheng S,Wang Y

    更新日期:2020-07-27 00:00:00

  • Long Non-Coding RNA BCAR4 Binds to miR-644a and Targets TLX1 to Promote the Progression of Bladder Cancer.

    abstract:Background:Bladder cancer is a serious threat to human health. It is meaningful to study the pathogenesis of bladder cancer. Long non-coding RNAs (lncRNAs) are reported to promote or inhibit bladder cancer development. However, the role of lncRNA BCAR4 in the regulation of bladder cancer remains unclear. Purpose:This ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S232965

    authors: Wang X,He H,Rui W,Xie X,Wang D,Zhu Y

    更新日期:2020-03-24 00:00:00

  • GSK1838705A, an insulin-like growth factor-1 receptor/insulin receptor inhibitor, induces apoptosis and reduces viability of docetaxel-resistant prostate cancer cells both in vitro and in vivo.

    abstract::Prostate cancer is the leading malignancy and the second most common cause of cancer-related death in men. Despite high cure rates with surgery and/or radiation, 30%-40% of patients eventually develop advanced cancer. Docetaxel is one of the most effective and well established chemotherapeutic agents for prostate canc...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S79105

    authors: Zhou F,Chen X,Fan S,Tai S,Jiang C,Zhang Y,Hao Z,Zhou J,Shi H,Zhang L,Liang C

    更新日期:2015-04-10 00:00:00

  • Evidence of response to pembrolizumab in a patient with Lynch syndrome-related metastatic colon cancer.

    abstract::Patients with Lynch Syndrome (LS) are at high risk of developing colorectal cancer at an early age. Germline mutations in DNA mismatch repair genes and microsatellite instability are clear signatures of this autosomal dominant disorder. Here, we report the clinical history of a 38-year-old patient with LS-related meta...

    journal_title:OncoTargets and therapy

    pub_type:

    doi:10.2147/OTT.S167645

    authors: Salman P,Panay S,Fernández R,Mahave M,Soza-Ried C

    更新日期:2018-10-23 00:00:00

  • Combination of CpG Oligodeoxynucleotide and Anti-4-1BB Antibody in the Treatment of Multiple Hepatocellular Carcinoma in Mice.

    abstract:Background:To investigate the effect of topical application of CpG oligodeoxynucleotide (CpG-ODN) combined with anti-4-1BB antibodies on mouse HCC multiple tumor-bearing models and the degree of improvement of anti-tumor immune response in mice. Materials and Methods:We inoculated each BALB/c male mouse subcutaneously...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S260353

    authors: Ma S,Yang X,Zhou H,Zhang C,Kang J,Sun D

    更新日期:2020-07-20 00:00:00

  • Molecular profiling in the treatment of colorectal cancer: focus on regorafenib.

    abstract::Metastatic colorectal cancer (mCRC) is a highly heterogeneous disease. Its treatment outcome has been significantly improved over the last decade with the incorporation of biological targeted therapies, including anti-EGFR antibodies, cetuximab and panitumumab, and VEGF inhibitors, bevacizumab, ramucirumab, and aflibe...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S79145

    authors: Yan Y,Grothey A

    更新日期:2015-10-15 00:00:00

  • Forkhead Box S1 Inhibits the Progression of Hepatocellular Carcinoma.

    abstract:Introduction:Forkhead box (FOX) superfamily members were recently shown to play important roles in tumor development and progression. Forkhead box S1 (FOXS1), a member of the FOX family, has been reported to be closely associated with malignant neoplasms. However, its expression and effect on hepatocellular carcinoma r...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S272596

    authors: Lei D,Hu G,Chen Y,Hao T,Gao Y,Luo F

    更新日期:2020-11-17 00:00:00

  • Celastrol induces ubiquitin-dependent degradation of mTOR in breast cancer cells.

    abstract:Background:Celastrol is a major active component of the thunder god vine (Tripterygium wilfordii) used in traditional Chinese medicine to treat chronic inflammatory and autoimmune diseases. Celastrol inhibits PI3K-Akt-mTOR signaling, which is frequently dysregulated in tumors and critical for tumor-cell proliferation a...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S187315

    authors: Li X,Zhu G,Yao X,Wang N,Hu R,Kong Q,Zhou D,Long L,Cai J,Zhou W

    更新日期:2018-12-11 00:00:00

  • Profile of selumetinib and its potential in the treatment of melanoma.

    abstract::The mitogen-activated protein kinase (MAPK) pathway is a critical oncogenic driver signal in a number of malignancies. The discovery of activating mutations in the MAPK pathway has led to the development of MAPK pathway inhibitors. Selumetinib is a potent and selective inhibitor of MEK1 and MEK2, which are essential d...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S51596

    authors: Kim DW,Patel SP

    更新日期:2014-09-19 00:00:00

  • Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report.

    abstract:BACKGROUND:Everolimus, an inhibitor of the mammalian target of rapamycin, shows promising antitumor activity when combined with trastuzumab and chemotherapy for human epidermal growth factor receptor-2 (HER2)-positive breast cancer or when combined with endocrine agents for hormone receptor (HR)-positive tumors. Howeve...

    journal_title:OncoTargets and therapy

    pub_type:

    doi:10.2147/OTT.S104398

    authors: Sun B,Ding L,Wu S,Meng X,Song S

    更新日期:2016-07-01 00:00:00

  • Clinical and radiological characteristics of central pulmonary adenocarcinoma: a comparison with central squamous cell carcinoma and small cell lung cancer and the impact on treatment response.

    abstract:Purpose:The proportion of central pulmonary adenocarcinoma (ADC) in central-type lung cancer has been gradually increasing due to the overall increasing incidence of pulmonary ADC. But the clinical and radiological characteristics of central ADCs remain unclear. In this study, we compared the clinical and radiological ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S154385

    authors: Wang Z,Li M,Huang Y,Ma L,Zhu H,Kong L,Yu J

    更新日期:2018-05-04 00:00:00

  • Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma.

    abstract::The epidermal growth-factor receptor (EGFR) is overexpressed in the majority of epithelial ovarian cancers and promotes cell proliferation, migration and invasion, and angiogenesis, as well as resistance to apoptosis. This makes EGFR an attractive therapeutic target in this disease. A number of strategies to block EGF...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S30373

    authors: Hirte HW

    更新日期:2013-04-18 00:00:00

  • Mast cells positive to tryptase, endothelial cells positive to protease-activated receptor-2, and microvascular density correlate among themselves in hepatocellular carcinoma patients who have undergone surgery.

    abstract:BACKGROUND:Mast cells (MCs) can stimulate angiogenesis, releasing several proangiogenic cytokines stored in their cytoplasm. In particular MCs can release tryptase, a potent in vivo and in vitro proangiogenic factor via proteinase-activated receptor-2 (PAR-2) activation and mitogen-activated protein kinase phosphorylat...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S105368

    authors: Ammendola M,Sacco R,Sammarco G,Piardi T,Zuccalà V,Patruno R,Zullo A,Zizzo N,Nardo B,Marech I,Crovace A,Gadaleta CD,Pessaux P,Ranieri G

    更新日期:2016-07-21 00:00:00

  • WHSC1 acts as a prognostic indicator and functions as an oncogene in cervical cancer.

    abstract::Purpose: Wolf-Hirschhorn syndrome candidate 1 (WHSC1) is an epigenetic modifier, considered to play a driving role in oncogenesis. However, very little is known about the roles of WHSC1 and its prognostic impacts in cervical cancer. This study aimed to investigate the role of WHSC1 in the prognosis of cervical cancer ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S204701

    authors: Wu J,Luo M,Duan Z,Jia Y,Linghu H,Tian P,Qi H

    更新日期:2019-06-17 00:00:00

  • Apatinib-treated advanced medullary thyroid carcinoma: a case report.

    abstract::Medullary thyroid carcinoma (MTC) is a rare malignancy originating from calcitonin-producing parafollicular C cells of the thyroid. Neither radiotherapy nor chemotherapy has demonstrated durable objective responses in patients with advanced MTC. Vandetanib and cabozantinib are the 2 tyrosine kinase inhibitors recently...

    journal_title:OncoTargets and therapy

    pub_type:

    doi:10.2147/OTT.S142598

    authors: Chen K,Gao Y,Shi F,Cao G,Bao J

    更新日期:2018-01-19 00:00:00

  • Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial.

    abstract:OBJECTIVES:Talimogene laherparepvec is the first oncolytic immunotherapy to receive approval in Europe, the USA and Australia. In the randomized, open-label Phase III OPTiM trial (NCT00769704), talimogene laherparepvec significantly improved durable response rate (DRR) versus granulocyte-macrophage colony-stimulating f...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S115245

    authors: Harrington KJ,Andtbacka RH,Collichio F,Downey G,Chen L,Szabo Z,Kaufman HL

    更新日期:2016-11-16 00:00:00